- Home
- HROW vs RCUS Comparison
HROW vs RCUS Comparison
Compare HROW & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HROW
- RCUS
- Stock Information
- Founded
- HROW 1998
- RCUS 2015
- Country
- HROW United States
- RCUS United States
- Employees
- HROW N/A
- RCUS N/A
- Industry
- HROW Biotechnology: Pharmaceutical Preparations
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- HROW Health Care
- RCUS Health Care
- Exchange
- HROW Nasdaq
- RCUS Nasdaq
- Market Cap
- HROW 1.1B
- RCUS 906.4M
- IPO Year
- HROW N/A
- RCUS 2018
- Fundamental
- Price
- HROW $33.02
- RCUS $9.43
- Analyst Decision
- HROW Strong Buy
- RCUS Buy
- Analyst Count
- HROW 7
- RCUS 8
- Target Price
- HROW $61.83
- RCUS $20.86
- AVG Volume (30 Days)
- HROW 453.8K
- RCUS 681.5K
- Earning Date
- HROW 08-11-2025
- RCUS 08-06-2025
- Dividend Yield
- HROW N/A
- RCUS N/A
- EPS Growth
- HROW N/A
- RCUS N/A
- EPS
- HROW N/A
- RCUS N/A
- Revenue
- HROW $212,858,000.00
- RCUS $141,000,000.00
- Revenue This Year
- HROW $46.17
- RCUS N/A
- Revenue Next Year
- HROW $39.97
- RCUS $28.73
- P/E Ratio
- HROW N/A
- RCUS N/A
- Revenue Growth
- HROW 53.49
- RCUS N/A
- 52 Week Low
- HROW $20.85
- RCUS $6.50
- 52 Week High
- HROW $59.23
- RCUS $18.98
- Technical
- Relative Strength Index (RSI)
- HROW 48.64
- RCUS 50.54
- Support Level
- HROW $30.12
- RCUS $8.84
- Resistance Level
- HROW $33.90
- RCUS $9.60
- Average True Range (ATR)
- HROW 1.70
- RCUS 0.45
- MACD
- HROW -0.50
- RCUS -0.04
- Stochastic Oscillator
- HROW 36.39
- RCUS 32.00
About HROW Harrow Inc.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.